ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ZD6474 (Vandetanib at the dose of 100 mg)|DRUG: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|DRUG: Fulvestrant|DRUG: ZD6474 (Vandetanib at the dose of 300 mg)|DRUG: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Sponsor: Genzyme, a Sanofi Company